

Knobbe Martens Olson & Bear LLP

Intellectual Property Law

550 West C Street
Suite 1200
San Diego CA 92101
Tel 619-235-8550
Fax 619-235-0176
www.kmob.com

Brenden S. Gingrich, Ph.D.
619-525-8321
Brenden.Gingrich@kmob.com

October 1, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Title: COMPOSITIONS FOR AFFECTING WEIGHT LOSS
Letters Patent No. 7,375,111
Issued: May 20, 2008
Our Reference: OREX.001A


Dear Sir:

Enclosed for filing is a Certificate of Correction in connection with the above-identified patent.

As the errors cited in the Certificate of Correction were incurred through the fault of the Patent Office, no fee is believed to be required. However, please charge our Deposit Account No. 11-1410 for any fees that may be incurred with this request.

Respectfully submitted,

Knobbe, Martens, Olson & Bear, LLP



Brenden Gingrich
Registration No. 60,295
Customer No. 20995

Enclosures

6009901
093008

Orange County
949-760-0404

San Francisco
415-954-4114

Los Angeles
310-551-3450

Riverside
951-781-9231

Seattle
206-405-2000

Washington, DC
202-640-6400

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,375,111
APPLICATION NO. : 10/828,795
ISSUE DATE : May 20, 2008
INVENTOR(S) : Eckard Weber, Michael Alexander Cowley

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 2, column 2, line 31, delete "1730:" and insert - - 1730; - -

Page 2, column 2, line 72, after "reducing" insert - - effects - -

Page 3, column 1, line 4, delete "Brian" and insert - - Brain - -

Page 3, column 2, line 1, delete "Enhancement" and insert - - Enhancement - -

Page 4, column 2, line 21, after "Caffeine" insert - - and - -

Column 2, line 63, delete "1-opioid" and insert - - μ -opioid - -

Column 3, line 40, delete "A-MSH," and insert - - α -MSH, - -

Column 5, line 57, delete "fosphenyloin" and insert - - fosphenytoin - -

Column 5, line 57, delete "phenyloin" and insert - - phenytoin - -

Column 9, line 49, delete "1-Subtype" and insert - - μ -Subtype - -

Column 30, line 67, delete " η -opioid" and insert - - κ -opioid - -

Column 41, lines 34-35, in Claim 1, delete "oral dosage form fixed combination." and insert - - oral fixed combination dosage form. - -

6009549
093008

MAILING ADDRESS OF SENDER:

Brenden Gingrich
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, California 92614

DOCKET NO. OREX.001A